Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cushing's Syndrome Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments - ResearchAndMarkets.com

Research and Markets
Posted on: 06 Mar 18

The "Cushing's Syndrome Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.

Cushing's syndrome currently exhibits a growing pipeline with 13 drug candidates.

Cushing's syndrome therapeutics pipeline in 2017

The study analyzed that the Cushing's syndrome therapeutics pipeline comprises of approximately 13 drug candidates.

Insights on pipeline segments

Orphan drug designations from the European Medicines Agency (EMA) is the one of the drivers for the development of pipeline drugs of Cushing's syndrome. Majority of the pipeline drug candidates are being developed using the oral route of administration. Osilodrostat which is being developed by the Novartis AG is in the Phase III stage of development for the treatment of Cushing's syndrome.

Positive clinical trial results propelling the growth of the pipeline

The existing drugs that are developed by the various pharmaceutical companies for the treatment of the disease have demonstrated positive clinical trial results, which in-turn is supporting their further development. For instance, Osilodrostat which is being developed by the Novartis AG demonstrated efficacy and well tolerated in the Phase II proof of concept study for the treatment of the Cushing's syndrome.

Specific Targeted Therapy to Provide Various Opportunities

The drug development process involves specific target such as steroid 11-beta-hydroxylase, which is the probable mechanism of action for the treatment of Cushing's syndrome. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development. Some of the players developing drugs for the treatment of Cushing's syndrome include Novartis AG, AstraZeneca Plc, Cyclacel Pharmaceuticals, Inc., and Angion Biomedica Corp.

Cushing's Syndrome Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered:

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

Chapter 5. Cushing's Syndrome Therapeutics Pipeline Analysis by Phase

Chapter 6. Clinical Trials Analysis

Chapter 7. Competitive Landscape

Chapter 8. Company Profiles

  • AstraZeneca plc
  • Novartis AG

For more information about this report visit https://www.researchandmarkets.com/research/blb8cm/cushings?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180306005857/en/

Business Wire
www.businesswire.com

Last updated on: 06/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.